Item 4 of the Original Schedule 13D is amended to include the following at the end thereof: "As previously disclosed, Gilead, Purchaser and Arcellx entered into the Merger Agreement pursuant to which Purchaser commenced the Offer on March 6, 2026. The Offer expired at 5:00 p.m., Eastern Time, on April 27, 2026. Computershare Trust Company N.A., the depositary and paying agent for the Offer, advised Gilead that, as of the expiration of the Offer, 38,795,604 Shares had been validly tendered and not validly withdrawn pursuant to the Offer, representing, together with Shares already owned by Gilead, approximately 77.2% of the Shares outstanding as of the expiration of the Offer. Following consummation of the Offer, on April 28, 2026, Gilead completed its acquisition of Arcellx through the merger of Purchaser with and into Arcellx, and without a meeting of the stockholders of Arcellx in accordance with Section 251(h) of the DGCL, with Arcellx surviving such Merger as a wholly owned subsidiary of Gilead. In connection with the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger (other than (i) Shares owned immediately prior to the effective time of the Merger by Arcellx (including those held in Arcellx's treasury), (ii) Shares owned both as of the commencement of the Offer and immediately prior to the effective time of the Merger by Gilead, Purchaser or any other direct or indirect wholly owned subsidiary of Gilead, (iii) Shares irrevocably accepted for purchase pursuant to the Offer and (iv) Shares held by stockholders who are entitled to appraisal rights under Section 262 of the DGCL and have properly exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided in Section 262 of the DGCL and, as of the effective time of the Merger, have neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL) was cancelled and converted into the right to receive on a per Share basis, (x) the Closing Amount in cash, without any interest thereon, subject to any withholding tax, plus (y) one CVR per Share (the Closing Amount plus one CVR, together, the "Offer Price"). As a result of the Merger, the 100 issued and outstanding shares of common stock, par value $0.001 per share, of Purchaser held by Gilead were converted into 100 issued and outstanding shares of common stock, par value $0.001 per share (the "New Shares"), of Arcellx. Consequently, Gilead became the beneficial owner of such 100 New Shares, which represent all of Arcellx's issued and outstanding shares of capital stock. Following the Merger, all Shares ceased trading prior to the opening of trading on the Nasdaq Global Select Market on April 28, 2026, and will be delisted from Nasdaq and deregistered under the Exchange Act."